AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04020692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EOPC Intervention
Description: The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization.
Study NCT02611570 — intervention group
Intervention type: OTHER
Intervention: LDCT
Description: LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
Study NCT04481230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
Study NCT04481230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
Study NCT04481230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
Description: 1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
Study NCT03301090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN3051
Description: REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
Study NCT01022801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
Study NCT02401308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation surgery
Description: Deep Brain Stimulation surgery: awake vs. asleep
Study NCT00984360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 380mg extended-release, given once by intramuscular gluteal injection
Study NCT02139423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMV PCR
Study NCT01736501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetics education at baseline
Study NCT01736501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypothetical genomic scenarios at follow-up
Study NCT01450605 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
Study NCT01103960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan80mg+Amlodipine5mg
Description: combination therapy
Study NCT01103960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5mg
Description: monotherapy
Study NCT01103960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan80mg+Amlodipine 5mg
Description: combination therapy
Study NCT04100512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillating Positive Expiratory Pressure Device
Description: Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
Study NCT04100512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometry
Description: An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
Study NCT02578914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS2 Ophthalmic Drops (0.5%)
Study NCT02578914 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: NS2 Ophthalmic Drops Vehicle (0.0%)
Study NCT01215214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam: 3mg iv
Study NCT01032044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopic evaluation
Description: Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
Study NCT01032044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pCLE guided evaluation
Description: Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
Study NCT02875834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 10g
Description: Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
Study NCT02875834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 5g
Description: Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
Study NCT02875834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 10g
Description: Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
Study NCT03638999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Trometamol 30Mg/1mL Injection
Description: Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
Study NCT03638999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
Study NCT03344692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
Study NCT03344692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prefilled pen containing 1 ml of solution without Praluent
Study NCT01118260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total intravenous anaesthesia
Description: propofol and remifentanil
Study NCT01118260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anaesthesia
Description: bupivacaine and fentanyl
Study NCT03976687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets
Study NCT01524939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunoglobulin G
Description: Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
Study NCT02105246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to home-based cardiac rehab
Description: Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
Study NCT02875834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Study NCT02876172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg MDMA (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.
Study NCT02876172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT
Description: A three-phase, 15-session, manualized treatment from the CBCT manual
Study NCT02876172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy (from the Multidisciplinary Association for Psychedelic Studies MDMA-assisted therapy treatment manual)
Study NCT03342053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: Intrathecal injection
Study NCT03696719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS bispectral index monitoring device
Description: In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
Study NCT03696719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NSE cerebral biomarker testing
Description: Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
Study NCT02105246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to center-based cardiac rehab
Description: Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
Study NCT03881930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation with modified visual input
Description: Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
Study NCT03881930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance rehabilitation with no modified visual input
Description: Patients will perform the exercises while keeping their eyes openned
Study NCT01456234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75 mg BID
Study NCT01456234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75 mg BID
Study NCT03265990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ligasure haemroidectomy
Description: In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
Study NCT03265990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional haemorrhoidectomy
Description: According to the Ferguson technique~* Manual anal sphincter stretching up to 4 fingers~* Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~* skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed.
Study NCT01586312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogenic mesenchymal stromal cells injection
Description: Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
Study NCT01586312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
Study NCT01362556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Administration of a calculated amount of sodium bicarbonate 8% \[SB\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SB \[ml\] = -BE \* kg \* 0.1
Study NCT01362556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Administration of a calculated amount of sodium chloride 0.9% \[SC\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SC \[ml\] = -BE \* kg \* 0.1
Study NCT01327118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin F2alpha
Description: intravenous injection
Study NCT01327118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoton sodium chloride
Description: intravenous injection
Study NCT04200313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas (BP) with Aspart or Lispro
Description: iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
Study NCT04200313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas with Fiasp (BPFiasp)
Description: iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
Study NCT04200313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Description: Using pre-study insulin regimen with the Dexcom G6 CGM
Study NCT04200313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: Using pre-study insulin regimen with the Dexcom G6 CGM
Study NCT04200313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BP Guidance Insulin Dosing
Description: Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
Study NCT00932334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TALK PLUS
Description: Participants receive and educational video and booklet about living kidney donation and meet with a social worker
Study NCT00932334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TALK Standard
Description: Participants receive and educational video and booklet about living kidney donation
Study NCT00932334 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants receive their usual care
Study NCT02693301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Study NCT00218803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse asthma education intervention
Description: Asthma Education
Study NCT00218803 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: Asthma Education
Study NCT03218696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Syrup for adults and children
Description: The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
Study NCT03218696 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
Study NCT00941564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula milk based
Description: Consume ad lib
Study NCT00941564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula milk based
Description: consume ad lib
Study NCT03152045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
Study NCT03987230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sensitive Eyes® Plus Saline Solution
Description: Sensitive Eyes® Plus Saline Solution
Study NCT03987230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oust™ Demodex® Wipes™
Description: Oust™ Demodex® Wipes™
Study NCT03987230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-LID N LASH PLUS® Eyelid Cleanser
Description: I-LID N LASH PLUS® Eyelid Cleanser
Study NCT03987230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephadex Lid Wipes
Description: Blephadex Lid Wipes
Study NCT03987230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Cleanse Lid Wipes
Description: Eye Cleanse Lid Wipes
Study NCT03987230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephademodex
Description: Blephademodex
Study NCT03004313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pet Scan
Description: Subjects will undergo Pet Scanning for 90 minutes
Study NCT03004313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pet Scan
Description: Subjects will undergo Pet Scanning for 90 minutes
Study NCT03004313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan
Study NCT03004313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Study NCT03004313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Testing (QST)
Study NCT03004313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST)
Study NCT02762734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDIA
Description: The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent.
Study NCT04496141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibody immunoassays
Description: Different commercial SARS-CoV-2 antibody immunoassays
Study NCT02443506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 623
Description: Single dose of AMG 623 administered as subcutaneous and intravenous doses
Study NCT02443506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
Study NCT03150524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCD- cerebral blood flow velocities
Description: Participants will undergo daily TCD for monitoring of cerebral blood flow.
Study NCT03150524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache pain score
Description: Participants will be evaluated by nurses for headache frequency and severity every shift.
Study NCT03150524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurological examination
Description: Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
Study NCT03150524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Repeat Neuroimaging
Description: All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
Study NCT03150524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Participants will be administered nimodipine every 4 hours.